KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) EBT Margin: 2018-2025

Historic EBT Margin for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Sep 2025 value amounting to 43.50%.

  • Aurinia Pharmaceuticals' EBT Margin rose 2166.00% to 43.50% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.96%, marking a year-over-year increase of 3910.00%. This contributed to the annual value of 3.17% for FY2024, which is 4731.00% up from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its EBT Margin stood at 43.50% for Q3 2025, which was up 37.46% from 31.65% recorded in Q2 2025.
  • Aurinia Pharmaceuticals' EBT Margin's 5-year high stood at 43.50% during Q3 2025, with a 5-year trough of -5,511.05% in Q1 2021.
  • Over the past 3 years, Aurinia Pharmaceuticals' median EBT Margin value was 1.96% (recorded in 2024), while the average stood at -6.02%.
  • Data for Aurinia Pharmaceuticals' EBT Margin shows a peak YoY increase of 14,498,500bps (in 2021) and a maximum YoY decrease of 12,344bps (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Aurinia Pharmaceuticals' EBT Margin stood at -139.28% in 2021, then skyrocketed by 5,068bps to -88.59% in 2022, then skyrocketed by 3,001bps to -58.58% in 2023, then soared by 6,054bps to 1.96% in 2024, then skyrocketed by 2,166bps to 43.50% in 2025.
  • Its last three reported values are 43.50% in Q3 2025, 31.65% for Q2 2025, and 38.98% during Q1 2025.